Non-small cell lung cancer

The PBS subsidises crizotinib and entrectinib for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with crizotinib and entrectinib under the National Health Act 1953, section 85 for patients with Stage IIIB or Stage IV NSCLC.

Patients must be eligible for the PBS and meet the restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing crizotinib and entrectinib.

Authority applications

Applying for initial treatment

Apply for initial authority approval to prescribe PBS subsidised crizotinib or entrectinib to treat Stage IIIB or Stage IV NSCLC in writing and either:

All written applications must include the completed:

Applying for initial grandfather treatment

For patients who received non-PBS subsidised entrectinib treatment before 1 August 2020 for Stage IIIB or Stage IV NSCLC, apply for initial grandfather authority approval in writing and either:

All applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS subsidised crizotinib or entrectinib to treat Stage IIIB or Stage IV NSCLC can be made either:

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 January 2021